Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Dec. 05, 2016 --

What:  
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Yuval Cohen, PhD, Chief Executive Officer and Director, will ring the Closing Bell. 

Where: 
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio 

When: 
Tuesday, December 6, 2016 – 3:45 p.m. to 4:00 p.m. ET  

Corbus Contact:
Jenene Thomas Communications
Jenene Thomas
908.996.0239
[email protected]  

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]   

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK  

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: 
http://www.facebook.com/NASDAQ.  

For photos from ceremonies and events, please visit our Instagram page: 
http://instagram.com/nasdaq 

For livestream of ceremonies and events, please visit our YouTube page: 
http://www.youtube.com/nasdaq/live 

For news tweets, please visit our Twitter page: 
http://twitter.com/nasdaq 

For exciting viral content and ceremony photos, please visit our Tumblr page: 
http://nasdaq.tumblr.com/  

Webcast: 
A live stream of the Nasdaq Closing Bell will be available at:  
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx   

Photos:  
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Corbus 
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Our lead product candidate, JBT-101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. JBT-101 is currently in Phase 2 clinical studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis, with a fourth Phase 2 trial in systemic lupus erythematosus planned to commence during the first half of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, Google+ and Facebook.  

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com 

-NDAQA-